100 TECHNOLOGY SQUARE, CAMBRIDGE, MA
Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
Announces Second Quarter 2026 Financial Results and Recent Business Highlights
Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Announces First Quarter 2026 Financial Results and Recent Business Highlights
Annual Report to Security Holders
Appoints Jessica Chutter to Board of Directors
Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Investor Presentation
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-8 POS
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement